NSTG VS IMMX Stock Comparison

Performance

NSTG
10/100

NSTG returned -82.21% in the last 12 months. Based on SPY's performance of -12.72%, its performance is below average giving it a score of 10 of 100.

IMMX
100/100

IMMX returned 229.13% in the last 12 months. Based on SPY's performance of -20.78%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

NSTG
65/100

5 analysts offer 12-month price targets for NSTG. Together, they have an average target of 0, the most optimistic target put NSTG at 0 within 12-months and the most pessimistic has NSTG at 0.

IMMX

"Analyst Price Targets" not found for IMMX

Sentiment

NSTG
71/100

NSTG had a bullish sentiment score of 70.90% across Twitter and StockTwits over the last 12 months. It had an average of 3.53 posts, 0.87 comments, and 4.33 likes per day.

IMMX
70/100

IMMX had a bullish sentiment score of 69.83% across Twitter and StockTwits over the last 12 months. It had an average of 19.63 posts, 8.56 comments, and 64.38 likes per day.

Technicals

NSTG
36/100

NSTG receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

IMMX
64/100

IMMX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

NSTG
10/100

NSTG has missed earnings 16 times in the last 20 quarters.

IMMX
14/100

IMMX has missed earnings 3 times in the last 20 quarters.

Profit

NSTG
10/100

Out of the last 20 quarters, NSTG has had 1 profitable quarters and has increased their profits year over year on 0 of them.

IMMX
10/100

Out of the last 12 quarters, IMMX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

NSTG
44/100

NSTG has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

IMMX
56/100

IMMX has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

All score calculations are broken down here to help you make more informed investing decisions

NanoString Technologies, Inc. Summary

Nasdaq / NSTG

Healthcare

Medical Instruments & Supplies

NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.

Immix Biopharma, Inc. Common Stock Summary

Nasdaq / IMMX

Healthcare

Biotechnology

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Power up your portfolio